Sumatriptan Injection Reduces Productivity Loss During a Migraine Attack
| Autor: | Robert E. Ryan, Stephen O'Quinn, Roger C. Cady, D. Gayla Pait, Priti Jhingran |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Adult
Male Work Migraine Disorders Placebo-controlled study Self Administration Efficiency Placebo Severity of Illness Index Double-Blind Method Recurrence Sumatriptan Succinate Internal Medicine Humans Vasoconstrictor Agents Medicine Dosing Sumatriptan business.industry medicine.disease Clinical trial Treatment Outcome Migraine Anesthesia cardiovascular system Female business Self-administration medicine.drug |
| Zdroj: | Archives of Internal Medicine. 158:1013 |
| ISSN: | 0003-9926 |
| DOI: | 10.1001/archinte.158.9.1013 |
| Popis: | To evaluate the impact of sumatriptan succinate injection compared with placebo on productivity loss during a migraine attack in the workplace.Randomized, double-blind, placebo-controlled, parallel-group clinical trial.Fifteen clinical centers in the United States.One hundred thirty-five patients 18 years and older diagnosed as having migraine according to International Headache Society criteria.Patients self-administered sumatriptan injection (6 mg) or matching placebo to treat a moderate or severe migraine occurring within the first 4 hours of a minimum 8-hour work shift.Mean productivity loss 2 hours after dosing and across the work shift; percentages of patients returning to normal work performance within 2 hours after dosing and across the work shift; percentages of patients experiencing headache relief (reduction of moderate or severe predose pain to mild or no pain) 1 and 2 hours after dosing.Mean productivity loss was significantly (Por =.002) lower in the sumatriptan group compared with the placebo group both during the 2-hour postdose period (sumatriptan, 39 minutes; placebo, 54 minutes) and across the work shift (sumatriptan, 86 minutes; placebo, 168 minutes). Significantly (P.001) greater percentages of patients in the sumatriptan group compared with the placebo group returned to normal work performance by 2 hours after dosing (sumatriptan, 52%; placebo, 9%) and across the work shift (sumatriptan, 66%; placebo, 18%). Significantly (Por =.001) greater percentages of patients in the sumatriptan group compared with the placebo group experienced headache relief 1 hour after dosing (sumatriptan, 69%; placebo, 18%) and 2 hours after dosing (sumatriptan, 79%; placebo, 32%).Sumatriptan reduced migraine-associated productivity loss during a minimum 8-hour work shift by approximately 50% compared with placebo and alleviated headache in more than three fourths of patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|